Journal of Nanomedicine & Nanotechnology

A clinical trial to evaluate the safety and immunogenicity of a novel DNA vaccine used as immunotherapy during leishmaniasis

4^th International Conference on Nanotek & Expo

December 01-03, 2014 DoubleTree by Hilton Hotel San Francisco Airport, USA

Laura Manna

Scientific Tracks Abstracts: J Nanomed Nanotechnol

Abstract:

Twenty leishmaniotic dogs from a leishmaniasis-endemic area (Naples, Italy) were enrolled in a clinical trial and were randomly assigned to receive three consecutive subcutaneous injections of vaccine at 10-days intervals (n=10\20), saline placebo (n=10\20). The vaccine was safe and well tolerated. Leishmania DNA load, IFAT, INF-λ and IL4 mRNA expression levels were tested before and after the immunotherapy, every 3 months for a period of 12 months. Analysis of the data indicated that the vaccine was safe and immunogenic in CVL dogs.

Biography :

Laura Manna has completed her PhD at the age of 28 years from Naples University and Postdoctoral studies from Naples University School of Veterinary Medicine. From 2005 she is a Researcher of Department of Veterinary Medicine and Animal Productions of University of Naples. Her research interest is to develop a protective vaccine for the prevention and treatment of leishmaniasis. She has published more than 25 papers in reputed journals.